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A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase
inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12mgm
 2 over
30min every 21 days. Fifty patients were treated. Median age was 64 years (range 35–82), 62% were male and 89% had ECOG PS of
0/1. A total of 252 cycles were administered; median of 4 per patient (range 1–21). Twelve patients required dose reductions, mainly
for skin toxicity. Investigator assessed response rate was 17.4% (95% CI 7.8–31.4) with one complete and seven partial responses in
46 evaluable patients. Twenty-one patients (42%) had stable disease. Median time to progression and survival were 12.4 and 36.9
weeks, respectively. NCI CTCAE Grade 3/4 neutropenia (14%) and thrombocytopenia (4%) were uncommon. The main G3/4
nonhaematological toxicities were skin-related 22%, stomatitis 14%, fatigue/lethargy 10%, and diarrhea 8%. Pharmacokinetic data
showed high interpatient variability. Patients with higher AUC were more likely to experience G3/4 toxicity during cycle 1 while
baseline homocysteine did not predict toxicity. Response did not correlate with AUC. Elevations in 20-dU were observed indicating
target inhibition. Analysis of TS genotype, TS protein and expression did not reveal any correlation with outcome. OSI-7904L has
activity in A-G/GEJA similar to other active agents and an acceptable safety profile.
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Gastric cancer is one of the leading causes of cancer death
worldwide, with an estimated 934000 new cases diagnosed
annually (Parkin et al, 2005). An estimated 22400 new cases are
diagnosed each year in the USA, with approximately 12100 deaths
in the same period (Jemal et al, 2003). In 2000, the estimated
incidence and mortality in Europe was 88002 and 71022,
respectively (Ferlay et al, 2001). In advanced disease, chemother-
apy has been shown to improve survival and quality of life in
comparison with supportive care alone (Glimelius et al, 1997).
Phase II studies have demonstrated single-agent response rates of
approximately 20% for a number of chemotherapeutic agents.
However, responses are mainly partial and of a short duration,
resulting in a median survival for patients with metastatic disease
of around 6–9 months (Schoffski, 2002; Ajani, 2005).
Combination chemotherapy regimens have been developed in
an effort to improve the outcome in advanced gastric cancer.
Currently, ECF (epirubicin/cisplatin/continuous 5-Fluorouracil
(5-FU)) or DCF (docetaxel/cisplatin/5-FU) combinations are
considered but both have significant toxicities, such that many
patients with advanced disease will not tolerate such treatment
(Webb et al, 1997; Vanhoefer et al, 2000; Ross et al, 2002;
Schoffski, 2002; Ajani, 2005; Moiseyenko et al, 2005).
OSI-7904 is a potent noncompetitive inhibitor of TS with a Ki
value of 90pM that does not require polyglutamation for maximal
enzyme inhibitory activity (Smith et al, 1999; Schwartz et al 2001).
OSI-7904 has been encapsulated into a liposomal formulation as
OSI-7904L. This formulation increases plasma residence, tissue
distribution and offers superior preclinical antitumour activity
compared to parent drug or 5-FU (Desjardins et al, 2004). A phase
I study with OSI-7904L utilising a day 1 every 21 days schedule
determined 12mgm
 2 as the recommended phase II dose (Beutel
et al, 2005). The toxicity profile was manageable and characteristic
of other TS inhibitors (TSIs), including skin-related, gastrointest-
inal, fatigue and myelosuppression. Eleven of 31 patients with a
variety of solid tumours achieved disease stabilisation despite
extensive prior therapy, including other TSIs. Pharmacokinetic
data from this trial demonstrated that in comparison to the
nonliposomal drug, the liposomal formulation OSI-7904L had
altered disposition properties and exhibited a longer plasma
circulation time. Plasma levels of 20-deoxyuridine (20-dU) were
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sfound to be elevated two- to four-fold for 4–7 days, indicating that
the target enzyme was inhibited following administration of OSI-
7904L (Beutel et al, 2005).
Several groups have identified potential biomarkers, which
might help predict outcome to TSIs in gastrointestinal malig-
nancies. Firstly, Park et al (2002) studied the relationship of the
promoter polymorphism in the TS gene – a 28 base pair tandem
repeat DNA present in two or three copies – with outcome in
patients with colorectal cancer who received capecitabine therapy.
While a small retrospective pilot study, they showed that patients
with a 2/2 polymorphism may have superior outcome to those
patients with 2/3 or 3/3 genotype. They also reported that a 2/2
polymorphism was more likely to predict increased toxicity.
Kawakami and Watanabe reported that a single nucleotide
polymorphism (SNP) in the triple repeat can affect expression so
that patients can be classified as either low or high expression type
(Kawakami and Watanabe, 2003). It has also been shown that TS
mRNA level and TS protein and gene expression can predict
outcome to chemotherapy with 5-FU/leucovorin based therapy
(Johnston et al, 1995; Lenz et al, 1995). In contrast, other authors
suggest TS protein and/or expression are not major predicting
factors for outcome to TSI-based therapy (Miyamoto et al, 2000;
Tsujitani et al, 2000).
This study was performed to evaluate the antitumour activity of
OSI-7904L in patients with advanced gastric or and gastroeso-
phageal junction adenocarcinoma (A-G/GEJA). It was designed as
a window study in order to test OSI-7904L in first-line patients
without exposure to prior fluoropyrimidine therapy, and in the
absence of clinical benefit, more commonly used combination
regimens could be introduced without negatively impacting
patient care. Additional biomarkers such as TS genotype, TS
protein and expression were included as optional investigations in
an attempt to identify potential predictive factors of outcome.
PATIENTS AND METHODS
Study design
This was an open-label, nonrandomised study to evaluate the
antitumour activity of OSI-7904L in previously untreated patients
with A-G/GEJA. The study complied with Good Clinical Practice
and the Declaration of Helsinki, and was approved by ethics
committees in all institutions prior to initiation. All patients gave
written informed consent for the clinical study and separately for
the genotype/biomarker study before trial entry.
Patient selection
Patients with A-G/GEJA were enrolled provided they met the
following criteria: age X18 years; ECOG performance status p2;
estimated life expectancy X3 months; no prior chemotherapy for
advanced disease; no radiation therapy within 28 days prior to
study entry; no concurrent anticancer therapy; adequate hemato-
poietic (neutrophilsX1.5 10
9l
 1 and plateletsX100 10
9l
 1);
hepatic (bilirubinp1.5 times upper limit of normal (ULN) and
serum AST and ALTp2.5 times ULN) and renal (serum
creatininep1.5 times ULN) function. Patients with symptomatic
or unstable brain metastases or a history of serious illness were not
enrolled.
Treatment and dose modification
OSI-7904L was supplied by OSI Pharmaceuticals Inc. Drug was
diluted in 5% dextrose in water and administered at 12mgm
 2 as
a 30min i.v. infusion repeated every 21 days.
Doses could be reduced to 9.6mgm
 2 and if required to
6.4mgm
 2 in case of: neutrophils o0.5 ( 10
9l
 1) for X7 days;
febrile neutropenia; CTCAE grade 3 infection with neutropenia;
platelets o25 ( 10
9l
 1) or thrombocytopenic bleeding and/or
CTCAE grade 3 nonhaematological toxicity. Any patient who failed
to tolerate a second dose reduction was to be withdrawn. No
routine premedication was required but any incidence of rash of
CTCAE grade 3 severity could be addressed with either a dose
reduction or by introduction of a steroid premedication at the
Investigator’s discretion.
Study investigations
Baseline assessment included complete medical history, physical
examination, vital signs, ECOG performance status, electrocardio-
gram, differential blood count and serum biochemistry (creatinine,
urea, total bilirubin, alkaline phosphatase, AST, ALT, total protein
and albumin). Baseline tumour burden was assessed by the
appropriate radiological investigation (e.g. spiral CT scans).
During treatment, assessments were repeated every three weeks
while a complete blood count was carried out weekly (twice weekly
in cycle 1). Investigator assessment of response was performed
every two cycles according to RECIST criteria (Therasse et al,
2000). Adverse events were evaluated according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) Version 3.0. Patients with disease progres-
sion were taken off study.
Sample collection and analysis
Plasma pharmacokinetics A total of seven blood samples were
collected during cycle 1 and optionally in cycle 2: predose, 0.5, 4,
24, 48 or 72 and 168h, then 22 days after the start of the infusion.
Blood samples were collected in EDTA tubes and then processed
and analysed for OSI-7904 concentration as previously reported
(Beutel et al, 2005). Plasma concentrations vs time data for OSI-
7904 were analysed by a noncompartmental method using
WinNonlin version 4.1.b (Pharsight Corporation, Mountain View,
CA, USA). Model 202 (i.v. infusion) was applied with linear/log
trapezoidal rule.
Plasma 20-dU Four plasma samples (4–5ml) were collected in
cycle 1: predose, 24, 48 or 72 and 168h after the end of infusion.
Samples were collected into tubes containing sodium fluoride
ethylenediamine tetra-acetic acid (NaF EDTA) and processed and
analysed for relative 20-dU concentration as previously reported
(Beutel et al, 2005).
Plasma homocysteine levels A blood sample (B5ml) was drawn
from all patients prior to the OSI-7904L infusion on day 1 of cycle
1. Each sample was collected into an EDTA tube, immediately
cooled on ice, and centrifuged at 1500–2000g for 10min under
refrigeration within 30min of collection. Equal aliquots of
separated plasma were transferred into two labelled cryovials
and frozen at  701C. Homocysteine concentrations in plasma were
determined using a fully automated Abbott Imx fluorescence
polarisation immunoassay (Fiskerstrand et al, 1993).
Biomarkers (i) TS/MTHFR genotype: A blood sample of 7–10ml
was collected into an EDTA tube and inverted several times
with anticoagulant immediately after collection before storage
at 41C. DNA was isolated using the Puregene kit from Gentra
Systems and genotyping performed using polymerase chain
reaction amplification, using primers flanking the repeat region
at the Department of Human Genetics at the University of Chicago.
Amplified products were then sized on an agarose gel (Horie et al,
1995). Samples were processed to assess TS genotype (i.e.
promoter polymorphism) and the SNP G-C within the promoter
(Kawakami and Watanabe, 2003; Mandola et al, 2003). Similar
methods were used to assess the MTHFR 677 C-T polymorphism
(Skibola et al, 1999).
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s(ii) Immunohistochemistry (IHC) studies: Formalin fixed,
paraffin-embedded tumour samples were received as 4–5mm
sections on plus slides or 4mm sections were cut from the paraffin
block provided. Immunohistochemistry staining was performed
using the DakoCytomation Autostainer. Briefly, deparaffinised
sections were treated with heat-induced epitope retrieval (HIER).
A pH 9 retrieval solution (code S2367) was used for 40min,
followed by a peroxidase blocking (code S2001) step for 5min. The
TS antibody (code M3614) was used at a 1:50 dilution for 30min
followed by the EnVisionþ labelled polymer anti-mouse System
(code K4000) for 30min. DAB substrate (code K3466) was used for
2–3min. Slides were then counter-stained, cleared and cover-
slipped.
(iii) Gene expression studies: Quantitative determination of TS
gene expression was assessed by RT–PCR from tumour samples
and analysed relative to b-actin at Response Genetics Inc., Los
Angeles, CA, USA (Schneider et al, 2004).
Statistics
The primary objective of this study was to determine the objective
response rate (ORR) of OSI-7904L in patients with untreated A-G/
GEJA. The secondary objectives were to: determine the time to
progression (TTP) and overall survival; determine the safety of
OSI-7904L; further evaluate the PK profile of OSI-7904L;
preliminarily evaluate any PK/PD correlation for safety and/or
efficacy and investigate any correlation of genotypes and/or
expression related to a patient’s outcome.
An optimal two-stage design was used where the estimated
response rate was based upon a low response rate of interest of
10% and a high response rate of interest of 25% (Simon, 1989). The
study was calculated to have an a-error of 5% and a b-error of
20%. Under these assumptions, 18 evaluable patients were to be
treated in Stage 1. At least three responses were required to
continue in to Stage 2 when an additional 25 evaluable patients
would be treated (up to a total of 43). If a total of eight responses
or more were observed, the drug would be declared active.
RESULTS
A total of 53 patients were enrolled into the study between October
2003 and June 2004 at 13 institutions in Europe and USA. Three
patients deteriorated rapidly so that 50 patients received OSI-
7904L. All 50 treated patients were evaluable for safety while 46
patients were evaluable for evaluation of response. Reasons for
nonevaluability were: no measurable disease, disease not reas-
sessed per protocol (two patients) and no disease reassessment.
Patient characteristics are listed in Table 1.
A total of 252 cycles of OSI-7904L were administered, with a
median of four per patient (range 1–21). Seventy-four percent
(187 out of 252) were delivered at the planned dose of 12mgm
 2
with 21% (52 out of 252) at 9.6, 4% (10 out of 252) at 9.0 and 1%
(three out of 252) at 6.4mgm
 2. Twelve patients had a dose
reduction, mainly for skin toxicity (9 patients). Other reasons for
dose reduction were (number of patients): stomatitis (2), diarrhea
(2), fatigue (2), nausea (1) and vomiting (1), with some patients
reporting more than one reason. Sixteen patients had cycle delays
of which four were due to OSI-7904L-related toxicity. Despite these
modifications, the median dose intensity and median relative dose
intensities were 3.92mgm
 2week
 1 and 98.0%, respectively.
Response
Eight patients were classified by the investigators as obtaining a
response according to RECIST (1 CR and 7 PRs). Thus, the
investigator assessed response rate was 16% (95%CI: 7.2–29.1) in
the 50 treated patients and 17.4% (95% CI: 7.8–31.4) in the 46
evaluable patients (Table 2). The median duration of response was
14.9 weeks (range 11.1–40.7). In addition, 21 patients (42%)
achieved SD, including four patients with minor responses or
unconfirmed partial response. The degree of tumour shrinkage in
patients with CR, PR or SD is shown in Figure 1. In the evaluable
population, the median TTP was 12.4 weeks (95% CI: 6.4–18.1). In
the overall population, the median survival was 36.9 weeks (95%
CI: 28.7–48.9) and 1-year survival was 31.8% (95% CI: 18.9–45.5).
Twenty-five patients (50%) received second-line therapy (chemo-
therapy in 24 and radiotherapy in 1). The most common second-
line regimen was ECF or some other platinum/TSI combination,
with other patients receiving taxane- or irinotecan-based
treatment.
All eight responses were among the 40 patients with gastric
primary with 0/10 in those with GEJ. Similar comparisons for the
same groups for TTP and overall survival were: TTP 17.6 weeks
(95% CI: 11.4–22.1) vs 6.2 weeks (95% CI: 5.3–8.6) and 42 weeks
(95% CI: 31.3–54.6) vs 18.65 weeks (95% CI: 13.10–41.7),
respectively.
Toxicity
The major haematological and nonhaematological toxicities
reported in 50 patients receiving at least one dose of OSI-7904L
are shown in Tables 3 and 4. The 30- and 60-day mortality was 2
and 12%, respectively. Cause of death was assigned to disease in all
cases.
Severe haematological toxicity was uncommon with a single case
of febrile neutropenia. The most common CTC grade 3/4
nonhaematological toxicities were skin-related with 22% of
patients (11 out of 50) reporting symptoms, including rash,
pruritis and erythema. Only one patient reported palmar-plantar
erythrodysaesthesia. Dose reduction and/or introduction of some
form of steroid premedication was found to ameliorate symptoms
and permit continued treatment without recurrence of similar
severity in the majority of patients. Other major CTC grade 3/4
toxicities included stomatitis/mucositis (14%), fatigue/lethargy
(10%) and diarrhoea (8%).
Table 1 Patient characteristics
No. of patients
(n¼53
a)
%o f
patients
Male/female 33/20 62/38
Median age (range) 64 years (35–82)
Gastric/GEJ 43/10 81/19
ECOG PS
02 0 3 8
12 7 5 1
26 1 1
Median time from diagnosis
(range)
58 days (13–1408)
Prior therapy
Surgery 37 70
Radiotherapy 5 9
Chemotherapy
b 48
Main sites of metastases
Lymph nodes 27 50
Liver 22 42
Lung 10 19
aThree patients were registered but deteriorated prior to dosing.
bNeo-adjuvant or
adjuvant setting.
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sPharmacokinetics and pharmacodynamics
Pharmacokinetic samples were collected from 48 patients in cycle 1
and five patients in cycle 2. Data confirmed a high level of
interpatient variability with patients differing in the amount of
drug cleared during the initial phase. Pharmacokinetic parameters
(median: range) were determined by noncompartmental analysis:
Cmax 4.76mgml
 1 (2.35–20.5), terminal half-life 53.7h (7.63–135)
and AUC 123hmgml
 1 (9.65–383). Cycle 2 data demonstrated that
there was low intrapatient variability with clearance consistent
across repeat dosing (data not shown).
Following the first OSI-7904L dose, plasma 20-dU levels were
elevated at least 1.5-fold in 24/27 (89%) patients with evaluable
data indicating that the target enzyme was inhibited. Data
indicated an increased risk of toxicity in patients with high AUC
during cycle 1 (P¼0.0049) (Figure 2). There was no relationship
(P¼0.8341) between baseline homocysteine and occurrence of
severe toxicity during cycle 1 (Figure 2). Finally, no correlation was
observed between AUC and investigator assessed response
(P¼0.6378, data not shown).
Plasma samples for TS genotype analyses were obtained from 37
(74%) patients. Seven (19%) were homozygous for the 2/2 repeat,
19 (51%) were 2/3 and 11 (30%) were 3/3. Analysis of the SNP in 34
patients further categorised these groups to high (16 (47%)) or low
(18 (53%)) expression-type on the presence of the G-C transition.
A total of 25 tumour samples (50%) were available for IHC
analysis. These were stained with M3614 antibody and categorised
Table 2 Response rate
All treated patients (n¼50) Evaluable patients (n¼46)
Investigator best response n (%) (95% CI) n (%) (95% CI)
Complete response 1 (2) — 1 (2) —
Partial response 7 (14) — 7 (15) —
Objective response (CR+PR) 8 (16) (7.2–29.1) 8 (17.4) (7.8–31.4)
Stable disease 21 (42) — 21 (46) —
Progressive disease 17 (34) — 17 (37) —
Not evaluable
a 4 (8) — — (0) —
aReasons for nonevaluable: no measurable disease, disease not reassessed per protocol (2 patients) and no disease reassessment.
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Figure 1 Illustration of percent tumour shrinkage in patients achieving
response or stable disease.
Table 3 Incidence of haematological toxicity per patient by maximum NCI CTC grade
NCI CTCAE severity grade (total n¼50)
Grade 1/2 Grade 3 Grade 4
Haematological toxicity n (%) n (%) n (%)
Total haemoglobin 40 (80) 6 (12) 1 (2)
Neutrophils 11 (22) 4 (8) 3 (6)
WBC 11 (22) 4 (8) 3 (6)
Platelet count 7 (14) 2 (4) 0 (0)
Table 4 Incidence of nonhaematological toxicity in X10% of patients by
preferred term and maximum NCI CTC grade
NCI CTCAE severity grade (Total n¼50)
G1/2 G3 G4
MedDRA system organ
class total preferred term n (%) n (%) n (%)
Gastrointestinal disorders 30 60 10 20 2 4
Nausea 29 58 2 4 0 0
Stomatitis 18 36 5 10 2 4
Diarrhoea 20 40 3 6 1 2
Vomiting 12 24 2 4 0 0
Constipation 5 10 0 0 0 0
General disorders and
administration site conditions
34 68 6 12 1 2
Fatigue 19 38 2 4 0 0
Lethargy 10 20 2 4 1 2
Pyrexia 10 20 1 2 0 0
Skin and subcutaneous tissue
disorders
28 56 10 20 1 2
Rash 20 40 8 16 0 0
Pruritus 19 38 1 2 0 0
Alopecia 11 22————
Metabolism and nutrition
disorders
20 40 3 6 0 0
Anorexia 18 36 2 4 0 0
Infections and infestations 10 20 1 2 1 2
Oral candidiasis 4800 12
Nervous system disorders 10 20 0 0 0 0
Dysgeusia 6 12 0 0 0 0
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sbased on intensity: 0 (3/25 (12%)), 1 (5/25 (20%)), 2 (10/25 (40%))
or 3þ (7/25 (28%)). Twenty (40%) samples were available for
expression analysis and median level was 4.05 (range 1.02–11.10)
relative to b-actin. There were no obvious correlations between the
individual measures of TS. No significant increase in TS protein
levels was detected by IHC in samples from two patients providing
pre/post-treatment biopsies. There were no apparent correlations
between TS genotype, SNP, IHC or expression in terms of TTP or
grade of toxicity. Equally, there was no increase in TTP or toxicity
for patients homozygous for the MTHFR 677 C-T polymorphism.
DISCUSSION
This Phase II trial with OSI-7904L was designed as a window study
in first-line A-G/GEJA to avoid prior exposure to 5-FU or other
TSIs in the advanced setting. Patients could be switched to
standard combination therapy in the absence of clinical benefit
with single agent OSI-7904L. However, the median duration of
treatment with OSI-7904L was four cycles and only one patient
received alternative therapy prior to progression. Twenty-four
patients (48%) crossed over to standard chemotherapy post
progression despite often prolonged treatment with OSI-7904L
demonstrating that OSI-7904L did not preclude second-line
therapy in many patients. The ability to administer second-line
therapy and overall survival similar to historical data suggest
similar window designs are feasible to test new agents in gastric
cancer (Webb et al, 1997; Ross et al, 2002). It was noted that the
small subset of GEJA patients (n¼10) appeared to have worse
outcome than those with stomach tumours. This was an
unexpected finding and contrasts with data from Ross et al
(2002), who concluded that the different populations faired equally
well with ECF treatment.
A second feature of this study was the collection of tissue and/or
blood for assessment of potential biomarkers. Although shown to
be feasible in this setting, the three different measures of TS
(genotype, IHC and expression) all appeared to be of limited use in
predicting outcome to OSI-7904L. The data generated showed no
correlation between the different measures themselves and unlike
other groups, failed to predict outcome based on any of the
markers examined (Johnston et al, 1995; Lenz et al, 1995; Park
et al, 2002; Kawakami and Watanabe, 2003). This may be
attributable to the fact that the majority of tumour samples were
retrieved from the original diagnostic block (Johnston et al, 2003).
The lack of correlation between genotype and outcome in this
study is similar to recent data from Sarbia et al (2006), who
demonstrated that the MTHFR C677T and TS tandem repeat
polymorphism had no predictive value in patients with oesopha-
geal squamous cell carcinoma undergoing multimodality treat-
ment.
The investigator assessed response rate of 17.4% is inferior to
the 25% defined in the protocol and insufficient to reject the null
hypothesis that the actual response rate could be less than 10%,
defined as the cutoff for inactivity. However, the disease
stabilisation rate demonstrates that many patients derived clinical
benefit (Figure 1), receiving multiple cycles using a simple once
every 21-day schedule with increased convenience. Other measures
of efficacy, such as median TTP and survival of 12.4 weeks (95%
CI: 6.4–18.1) and 36.9 weeks (95% CI: 28.7–48.9), respectively,
also offer acceptable comparison to other specific and multi-
targeted TSIs, albeit in an uncontrolled manner (Schoffski, 2002;
Ajani, 2005).
Nonhaematological toxicities were characteristic for this drug
class: mainly skin, fatigue and gastrointestinal but there was a
relatively low incidence of severe myelosuppression. A subset of
patients experienced severe toxicity, and in addition to the 12
patients with reductions, five patients withdrawn during cycle 1
would have required a reduction had they continued on study,
suggesting up to one-third of patients could not tolerate
12mgm
 2. However, dose reduction and/or dexamethasone
prophylaxis appeared to ameliorate skin-related symptoms in
most patients, facilitating repeat dosing. Unlike pemetrexed and
plivatrexed, baseline homocysteine did not predict cycle 1 toxicity,
suggesting that folate/vitamin B12 supplementation is not required
or useful in preventing toxicity as it is with those agents (Niyikiza
et al, 2002, Thomas et al, 2005).
The high level of interpatient variability in OSI-7904L clearance
seen in the phase I trial of OSI-7904L was again evident (Beutel
et al, 2005). Those patients with higher AUC were more likely to
experience a CTC grade 3/4 toxicity (Figure 2). A similar
observation was made between fluorouracil AUC and toxicity
following administration of S-1 and cisplatin (Ajani et al, 2005).
Ajani et al hypothesised that differential metabolism of the
protective constituent (Oxo) or polymorphic differences in the
CYP2A6 gene as well as single dose PK may be important factors in
attempting to assess the risk of toxicity with S-1 administration. In
contrast, the utility of OSI-7904L may be hampered by the inability
to predict the extent of exposure (due to the variability in initial
clearance or alpha phase) and the fact that neither homocysteine
nor genotype appeared to predict toxicity. The low intrapatient
variability in PK suggests that monitoring blood levels following an
initial lower dose of OSI-7904L might be a useful guide to longer
term administration. There was no correlation between AUC and
response, suggesting that OSI-7904L may not need to be
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Figure 2 High plasma AUCs were associated with a greater risk of
experiencing a grade 3 or 4 toxicity (upper panel) during dose cycle 1
(P¼0.0049) while baseline plasma homocysteine concentration (lower
panel) was not (P¼0.8341). Bars represent median values.
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sadministered at doses as high as 12mgm
 2. Beutel et al (2005)
inferred that toxicity might not be the most appropriate predictor
for dose assessment, suggesting some other pharmacodynamic
marker may be considered such as 20-dU. Unfortunately, while 20-
dU elevations were seen in this study, there did not appear to be
any correlation with either toxicity or response.
In conclusion, the activity of OSI-7904L in A-G/GEJA appears
borderline, though broadly similar to other agents, in terms of
response rate, TTP and overall survival (Schoffski, 2002; Ajani,
2005). Overall the toxicity profile was manageable and adminis-
tration with dexamethasone premedication is recommended to
increase tolerability. The degree of disease stabilisation and
duration of treatment are of note in this setting where disease
palliation is a primary goal. The addition of a platinum agent
might offer additional improvements in response or survival,
similar to other TSI/platinum combinations (Schoffski, 2002; Ajani
et al, 2005; Ajani, 2005). Preclinical data showing additive activity
when OSI-7904L was combined with cisplatin or oxaliplatin have
been reported and a phase I study combining OSI-7904L with
cisplatin has been completed (Winski et al, 2004; Ricart et al,
2005). The dose of OSI-7904L was reduced to 7.5mgm
 2 in order
to administer the drug safely in combination with 75mgm
 2 of
cisplatin and may offer an improved therapeutic index compared
to the single-agent dose of 12mgm
 2. Less skin toxicity was noted
than that seen in these patients, probably as a consequence of the
lower OSI-7904L dose as well as dexamethasone administered as
antiemetic premedication for cisplatin. Despite the lower dose of
OSI-7904L, responses were reported in three out of 27 patients,
including a patient with gastric cancer (Ricart et al, 2005). Data
from a study combining OSI-7904L and oxaliplatin are also
awaited.
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